Ascension Capital Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History
Bought
Maintained
Sold
Other funds holding ARKG
MCM
CAN
Ascension Capital Advisors's ARKG Position: Q4 2020 in Review
Ascension Capital Advisors sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2020, closing a stake of 4,580 shares — an estimated $292K sold.
Ascension Capital Advisors first reported a position in ARKG in Q2 2020 and held it in 2 quarters. The position peaked at $292K in Q3 2020. 414 funds tracked by Wall St. Rank hold ARKG as of Q4 2020.
- Ascension Capital Advisors reported no remaining ARK Genomic Revolution ETF position as of Q4 2020 after selling out during the quarter.
- Ascension Capital Advisors sold 4,580 ARK Genomic Revolution ETF shares in Q4 2020, an estimated $292K.
- Ascension Capital Advisors first reported a position in ARK Genomic Revolution ETF in Q2 2020 and held it in 2 quarters.
- Ascension Capital Advisors's ARK Genomic Revolution ETF position peaked at $292K in Q3 2020.
- 414 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2020.
Based on Ascension Capital Advisors's 13F filing for Q4 2020, filed 17 Feb 2021.